{"id":"W4402560121","doi":"10.1016/j.annonc.2024.08.685","title":"618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007225898,0.001098344,0.00183418,0.0004675914,0.0003825856,0.001038417,0.0008120083,0.001041849,0.00885966],"category_scores_gemma":[0.0003536602,0.0004759618,0.00125131,0.0003088002,0.0006744167,0.0008968863,0.0003791423,0.002874612,0.00202017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013927,"about_ca_system_score_gemma":0.001385532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001246892,"about_ca_topic_score_gemma":0.005054604,"domain_scores_codex":[0.9997534,0.00005979235,0.00000912291,0.00004008821,0.00002659669,0.0001109318],"domain_scores_gemma":[0.9998007,0.0000197824,0.00002048172,0.00001850775,0.00001149835,0.000129089],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4207039,0.05530701,0.006456672,0.00130975,0.002463394,0.0004819634,0.0002924103,0.005837324,0.06811094,0.002618607,0.03116017,0.4052579],"study_design_scores_gemma":[0.5270231,0.4123313,0.01178761,0.0001385739,0.0009884774,0.0009398473,0.0001358212,0.004993667,0.01097914,0.001362163,0.02924642,0.00007382386],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9656032,0.008811365,0.001527382,0.002119971,0.0006681625,0.003105853,0.003759688,0.0004699298,0.01393441],"genre_scores_gemma":[0.9635286,0.005983609,0.002843556,0.00244026,0.0002696356,0.002517432,0.007275436,0.00008274967,0.01505885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00885966,"threshold_uncertainty_score":0.02963853,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08902763781321484,"score_gpt":0.3976565212249891,"score_spread":0.3086288834117742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}